公开(公告)号：WO2007002088A2

公开(公告)日：2007-01-04

申请号：PCT/US2006/023980

申请日：2006-06-20

Applicant: EXELIXIS, INC. ,  BRACE, Arthur ,  BJERKE, Lynn, Margaret ,  NIETO-BERGMAN, Susana ,  FRIEDMAN, Lori, S. ,  WARD, Kevin ,  BLAKE, Robert, A.

Inventor： BRACE, Arthur ,  BJERKE, Lynn, Margaret ,  NIETO-BERGMAN, Susana ,  FRIEDMAN, Lori, S. ,  WARD, Kevin ,  BLAKE, Robert, A.

IPC: A61K38/54

CPC classification number: C12N9/14 ,  G01N33/574 ,  G01N33/6872 ,  G01N2333/4704 ,  G01N2333/9121 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2510/00

Abstract: Human PSATl genes are identified as modulators of the PTEN/AKT pathway, and thus are therapeutic targets for disorders associated with defective PTEN/AKT function. Methods for identifying modulators of PTEN/AKT, comprising screening for agents that modulate the activity of PSATl are provided.

Abstract translation: 人PSAT1基因被鉴定为PTEN / AKT途径的调节剂，因此是与缺陷PTEN / AKT功能相关的病症的治疗靶标。 提供了鉴定PTEN / AKT调节剂的方法，包括筛选调节PSAT1活性的试剂。

公开(公告)号：WO2006126198A2

公开(公告)日：2006-11-30

申请号：PCT/IL2006/000613

申请日：2006-05-24

Applicant: SIMETRA PHARM LTD. ,  LARISCH, Sarit

Inventor： LARISCH, Sarit

IPC: A61K38/54 ,  C07K14/47

CPC classification number: C07K14/4747 ,  A61K38/00

Abstract: This invention provides isolated peptides comprising a C-terminal fragment of an ARTS protein, isolated nucleotides encoding same, mimetics and small molecule analogues of same, and therapeutic applications comprising administering a peptide, nucleic acid, or mimetic compound of the present invention. This invention also provides isolated complexes comprising a C-terminal fragment of an ARTS protein and either an IAP protein, a Bir3 domain thereof, or a fragment thereof; compounds that bind or interact with same, and use of the compounds in therapeutic applications.

Abstract translation: 本发明提供了分离的肽，其包含ARTS蛋白的C末端片段，编码它的分离的核苷酸，模拟物及其相同的小分子类似物，以及包括施用本发明的肽，核酸或模拟化合物的治疗应用。 本发明还提供了包含ARTS蛋白的C末端片段和IAP蛋白，其Bir3结构域或其片段的分离的复合物; 与其结合或相互作用的化合物，以及在治疗应用中使用该化合物。

公开(公告)号：WO2006113429A2

公开(公告)日：2006-10-26

申请号：PCT/US2006014056

申请日：2006-04-13

Applicant: XC RES INC ,  CUI XIANGMIN

Inventor： CUI XIANGMIN

IPC: A61K38/54

CPC classification number: C07K14/005 ,  A61K38/00 ,  C12N2710/10022 ,  C12N2720/12322 ,  C12N2730/10122 ,  C12N2760/16122 ,  C12N2760/18622 ,  C12N2770/20022 ,  C12N2770/24122 ,  C12N2770/24222 ,  G06F19/18 ,  G06F19/22

Abstract: The present invention claims and discloses methods of identifying proteins and/or peptide that inhibit viral infection for the treating, preventing and/or ameliorating of an infection caused by a virus. The application also claims and discloses formulations and specific peptides identified using the disclosed methods.

Abstract translation: 本发明要求并且公开了鉴定抑制病毒感染以治疗，预防和/或改善由病毒引起的感染的蛋白质和/或肽的方法。 本申请还要求和公开使用所公开的方法鉴定的制剂和特异性肽。

公开(公告)号：WO2006107946A2

公开(公告)日：2006-10-12

申请号：PCT/US2006012460

申请日：2006-04-04

Applicant: BALABAN NAOMI

Inventor： BALABAN NAOMI

IPC: A61K38/54

CPC classification number: A61K38/08 ,  A61F2002/2817 ,  A61F2310/00353 ,  A61L24/0015 ,  A61L24/02 ,  A61L24/06 ,  A61L24/108 ,  A61L2300/252 ,  A61L2300/402 ,  A61L2300/404 ,  A61L2300/406 ,  A61L2300/412 ,  A61L2300/624 ,  A61L2430/02 ,  C08L33/12

Abstract: RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Unlike antibiotics, RIP eradicates biofilms without inducing resistant bacterial strains, making RIP particularly advantageous in this application. Biodegradable compositions comprising RIP also are provided.

Abstract translation: RNAIII抑制肽（RIP）有利地治疗或降低植入的骨水泥上生物膜形成的风险，从而减少持续化疗，住院或手术去除骨水泥的可能性。 与抗生素不同，RIP消除生物膜而不诱导抗性细菌菌株，使RIP在本应用中特别有利。 还提供包含RIP的可生物降解组合物。

公开(公告)号：WO2006088906A2

公开(公告)日：2006-08-24

申请号：PCT/US2006/005239

申请日：2006-02-14

Applicant: DANA-FARBER CANCER INSTITUTE, INC. ,  KUFE, Donald, W.

Inventor： KUFE, Donald, W.

IPC: A61K38/54

CPC classification number: C07K14/4727 ,  A61K31/713 ,  A61K38/1709 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1098

Abstract: The invention provides methods of identifying and making compounds that inhibit the interaction between MUCl and either p53 or TBP. Also embraced by the invention are in vivo and in vitro methods of inhibiting such an interaction and of inhibiting the expression of MUCl by a cell.

Abstract translation: 本发明提供鉴定和制备抑制MUC1与p53或TBP之间相互作用的化合物的方法。 本发明还包括抑制这种相互作用并抑制细胞表达MUCl的体内和体外方法。

公开(公告)号：WO2005099749A3

公开(公告)日：2006-08-03

申请号：PCT/US2005011549

申请日：2005-04-05

Applicant: CANYON PHARMACEUTICALS INC ,  YU CHENG-DER TONY

Inventor： YU CHENG-DER TONY

IPC: A01N37/18 ,  A61K38/00 ,  A61K38/54 ,  A61K38/58

CPC classification number: A61K38/58 ,  A61K2300/00

Abstract: The present invention relates generally to methods of inhibiting angiogenesis in a patient by administering an effective angiogenesis-inhibiting amount of a thrombin inhibitor, and to the treatment of disease states that result from uncontrolled cell proliferation by administering a thrombin inhibitor alone or co-administering a thrombin inhibitor with an anticancer or cytotoxic agent. Specifically, the thrombin inhibitors used in the methods of the present invention are hirudins.

Abstract translation: 本发明一般涉及通过施用有效的血管生成抑制量的凝血酶抑制剂和通过单独施用凝血酶抑制剂或共同施用治疗由不受控制的细胞增殖而引起的疾病状态来抑制患者血管生成的方法 具有抗癌剂或细胞毒性剂的凝血酶抑制剂。 具体地，本发明的方法中使用的凝血酶抑制剂是水蛭素。

公开(公告)号：WO2005074633A3

公开(公告)日：2006-05-26

申请号：PCT/US2005003419

申请日：2005-02-03

Applicant: UNIV MICHIGAN ,  CLARKE MICHAEL F ,  AL-HAJJ MUHAMMAD

Inventor： CLARKE MICHAEL F ,  AL-HAJJ MUHAMMAD

IPC: C12Q1/68 ,  A61K38/00 ,  A61K38/54 ,  A61K39/395 ,  C07K16/28 ,  G01N33/53 ,  G01N33/574

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K38/005 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2863 ,  C07K16/3015 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  G01N33/57415 ,  G01N33/57484

Abstract: The present invention relates to compositions and methods for characterizing, regulating, diagnosing, and treating cancer. For example, the present invention provides compositions and methods for inhibiting tumorigenesis of certain classes of cancer cells, including breast cancer cells and preventing metastasis. The present invention also provides systems and methods for identifying compounds that regulate tumorigenesis.

Abstract translation: 本发明涉及用于表征，调节，诊断和治疗癌症的组合物和方法。 例如，本发明提供抑制某些类型的癌细胞（包括乳腺癌细胞）和预防转移的肿瘤发生的组合物和方法。 本发明还提供用于鉴定调节肿瘤发生的化合物的系统和方法。

公开(公告)号：WO2006044614A2

公开(公告)日：2006-04-27

申请号：PCT/US2005036959

申请日：2005-10-14

Applicant: SOPHERION THERAPEUTICS INC ,  RASTELLI LUCA ,  LANDIN JUDITH ,  MALYANKAR URIEL ,  KISTON RICHARD ,  CORSO MELISSA ,  BRUNSON KENNETH

Inventor： RASTELLI LUCA ,  LANDIN JUDITH ,  MALYANKAR URIEL ,  KISTON RICHARD ,  CORSO MELISSA ,  BRUNSON KENNETH

IPC: A61K38/54

CPC classification number: C07K14/475 ,  A61K38/00 ,  A61K47/62 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001

Abstract: Anti-angiogenic peptides that inhibit activation or proliferation of endothelial cells are disclosed. Such peptides maybe used to inhibit VEGF binding to the VEGFR2 receptor (also known as the kinase domain receptor or KDR) and bFGF binding to its receptor. Such peptides may also be used to inhibit, VEGF, bFGF, or integrin activation of endothelial cells in angiogenesis-associated diseases such as cancer, leukemia, multiple myeloma, inflammatory diseases, eye diseases and skin disorders.

Abstract translation: 公开了抑制内皮细胞活化或增殖的抗血管生成肽。 这样的肽可以用于抑制VEGF结合VEGFR2受体（也称为激酶结构域受体或KDR）和bFGF与其受体的结合。 这些肽也可用于抑制血管生成相关疾病如癌症，白血病，多发性骨髓瘤，炎性疾病，眼睛疾病和皮肤疾病中的VEGF，bFGF或整合素激活内皮细胞。

公开(公告)号：WO2006034007A2

公开(公告)日：2006-03-30

申请号：PCT/US2005033076

申请日：2005-09-16

Applicant: CURAGEN CORP ,  ORT TATIANA A

Inventor： ORT TATIANA A

IPC: A61K38/54

CPC classification number: C12N9/1205

Abstract: The invention relates to salt-inducible serine/threonine kinase polypeptides that are targets of small molecule drugs and that have properties relates to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. Methods of use encompass screening, diagnostic and prognostic assay procedures as well as methods of treating diverse metabolic disorders.

Abstract translation: 本发明涉及作为小分子药物靶标的盐诱导型丝氨酸/苏氨酸激酶多肽，其具有与细胞，组织，器官或生物体中的生化或生理反应的刺激有关的特性。 使用方法包括筛查，诊断和预后测定程序以及治疗不同代谢紊乱的方法。

公开(公告)号：WO2006012365A2

公开(公告)日：2006-02-02

申请号：PCT/US2005025786

申请日：2005-07-20

Applicant: UNIV MARYLAND ,  TAYLOR LARRY EDMUND II ,  WEINER RONALD M ,  HUTCHESON STEVEN W

Inventor： TAYLOR LARRY EDMUND II ,  WEINER RONALD M ,  HUTCHESON STEVEN W

IPC: A61K38/54

CPC classification number: C07K14/8107 ,  A61K38/00

Abstract: The present disclosure provides isolated nucleic acids and their resulting polypeptides from Saccharophagus degradans strain 2-40, which may be utilized as protease inhibitors.

Abstract translation: 本公开提供了可以用作蛋白酶抑制剂的来自Saccharophagus degradationans菌株2-40的分离的核酸及其得到的多肽。